These insights highlight the COL6A2-integrin axis as a potential biomarker and therapeutic target in ccRCC and provide a rationale for strategies that disrupt ECM-integrin interactions to temper Wnt/β-catenin activity. This evidence concerns the gene MMRN1 and nonpapillary renal cell carcinoma.